Figure 4.
Mechanism of treatment-emergent hypophosphatemia. Following the administration of some intravenous iron formulations is a sharp rise in the plasma iFGF23, triggering a pathophysiological cascade of renal phosphate wasting, calcitriol deficiency, and secondary hyperparathyroidism. This frequently culminates in hypophosphatemia even after iFGF23 levels have normalized. PTH, parathyroid hormone.

Mechanism of treatment-emergent hypophosphatemia. Following the administration of some intravenous iron formulations is a sharp rise in the plasma iFGF23, triggering a pathophysiological cascade of renal phosphate wasting, calcitriol deficiency, and secondary hyperparathyroidism. This frequently culminates in hypophosphatemia even after iFGF23 levels have normalized. PTH, parathyroid hormone.

Close Modal

or Create an Account

Close Modal
Close Modal